These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
410 related items for PubMed ID: 15800660
1. Inhibition of NF-kappaB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy. Palmer DH, Chen MJ, Searle PF, Kerr DJ, Young LS. Gene Ther; 2005 Aug; 12(15):1187-97. PubMed ID: 15800660 [Abstract] [Full Text] [Related]
2. Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. Chen MJ, Green NK, Reynolds GM, Flavell JR, Mautner V, Kerr DJ, Young LS, Searle PF. Gene Ther; 2004 Jul; 11(14):1126-36. PubMed ID: 15164095 [Abstract] [Full Text] [Related]
5. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. Palmer DH, Mautner V, Mirza D, Oliff S, Gerritsen W, van der Sijp JR, Hubscher S, Reynolds G, Bonney S, Rajaratnam R, Hull D, Horne M, Ellis J, Mountain A, Hill S, Harris PA, Searle PF, Young LS, James ND, Kerr DJ. J Clin Oncol; 2004 May 01; 22(9):1546-52. PubMed ID: 15051757 [Abstract] [Full Text] [Related]
6. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes. Hu ZB, Wu CT, Wang H, Zhang QW, Wang L, Wang RL, Lu ZZ, Wang LS. Cancer Gene Ther; 2008 Mar 01; 15(3):173-82. PubMed ID: 18157145 [Abstract] [Full Text] [Related]
9. Towards gene therapy in prosthesis loosening: efficient killing of interface cells by gene-directed enzyme prodrug therapy with nitroreductase and the prodrug CB1954. de Poorter JJ, Tolboom TC, Rabelink MJ, Pieterman E, Hoeben RC, Nelissen RG, Huizinga TW. J Gene Med; 2005 Nov 01; 7(11):1421-8. PubMed ID: 15977303 [Abstract] [Full Text] [Related]
10. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. Searle PF, Chen MJ, Hu L, Race PR, Lovering AL, Grove JI, Guise C, Jaberipour M, James ND, Mautner V, Young LS, Kerr DJ, Mountain A, White SA, Hyde EI. Clin Exp Pharmacol Physiol; 2004 Nov 01; 31(11):811-6. PubMed ID: 15566399 [Abstract] [Full Text] [Related]
11. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Plumb JA, Bilsland A, Kakani R, Zhao J, Glasspool RM, Knox RJ, Evans TR, Keith WN. Oncogene; 2001 Nov 22; 20(53):7797-803. PubMed ID: 11753658 [Abstract] [Full Text] [Related]
12. Virus-directed enzyme prodrug therapy using CB1954. Grove JI, Searle PF, Weedon SJ, Green NK, McNeish IA, Kerr DJ. Anticancer Drug Des; 1999 Dec 22; 14(6):461-72. PubMed ID: 10834268 [Abstract] [Full Text] [Related]
14. Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954. Lukashev AN, Fuerer C, Chen MJ, Searle P, Iggo R. Hum Gene Ther; 2005 Dec 22; 16(12):1473-83. PubMed ID: 16390278 [Abstract] [Full Text] [Related]